Video interview: Detecting potentially treatable causes of cognitive decline

By The Science Advisory Board staff writers

Quest Diagnostics recently announced the nationwide availability of the RestoreU Dementia Panel, an artificial intelligence (AI)-based risk assessment and care service created by uMethod Health.

In this video interview, Dr. Michael K. Racke, medical director for neurology at Quest Diagnostics, spoke to Stephen Wellman, director of content and strategy at LabPulse and The Science Advisory Board, about the challenges associated with identifying those who do not have Alzheimer's and may have reversible conditions that mimic dementia.

The RestoreU service seeks to help address such challenges by incorporating the results of laboratory tests ordered by physicians from Quest along with the patient's health history, including comorbidities, lifestyle habits, and medications. uMethod’s AI platform then assesses 50-plus risk factors, pinpointing areas of concern and ultimately generating a personalized care plan with evidence-based, actionable treatment recommendations.

Detecting potentially treatable causes of cognitive decline

FDA approves first drug to treat agitation associated with dementia due to Alzheimer’s
The U.S. Food and Drug Administration (FDA) on Thursday announced the supplemental approval of Rexulti (brexpiprazole) oral tablets for the treatment...
Alzheimer’s drug could prevent damage to the brain
Researchers showed that tiny aggregates of amyloid beta protein, a naturally occurring substance associated with Alzheimer’s disease progression, can...
Aiming targeted protein degradation at kinase unlocks potential way to treat Alzheimer’s
A targeted protein degrader could break apart a kinase implicated in Alzheimer’s disease to improve the cognitive abilities of patients with the neurodegenerative...
Blood biomarker facilitates vascular dementia diagnosis
A National Institutes of Health (NIH)-funded consortium has found that measuring a key blood molecule may identify the degree to which impaired blood...
Analysis of genome-wide methylomic variations reveal epigenetic changes in Alzheimer’s brains
DNA methylation affects gene and protein co-expression networks associated with Alzheimer’s disease and offers a novel way to treat the condition, according...
Biomarkers reveal Alzheimer’s years before symptoms show
Karolinska Institutet researchers and their colleagues found that a protein called GFAP is a possible biomarker for very early stages of an inherited...

Copyright © 2023

Last Updated mp 5/12/2023 3:54:39 PM